Information Provided By: 
Fly News Breaks for May 9, 2017
HZNP
May 9, 2017 | 06:56 EDT
Jefferies analyst David Steinberg lowered his price target for Horizon Pharma to $14 saying the company's "primary care strategy finally hit a wall" in Q1. Conversely, the orphan business performed well, the analyst tells investors in a post-earnings research note. While the stock may be in the penalty box for some time, the orphan business could be valued at or in excess of the entire company, Steinberg contends. He keeps a Buy rating on Horizon.
News For HZNP From the Last 2 Days
There are no results for your query HZNP
